Covetrus
Global animal-health distributor and veterinary software
Contract & Corporate Generalist
+ Short-term incentive
More locations: Ohio, USA
About the job
- At least 5 years of corporate paralegal experience, preferably in an in-house legal department or a major corporate law firm.
- Significant experience drafting, reviewing, and negotiating complex contracts for products the company buys and sells, software as a service, and complex artificial-intelligence-based vendors.
- A bachelor's degree is required; the employer is willing to consider a junior lawyer.
- Ability to operate efficiently in legal systems, including contract lifecycle management, workflow, and matter-management platforms, and to support others using those systems.
- Experience collaborating with cross-functional departments.
- Experience working with playbooks to assist in contract reviews.
- Strong contract drafting, reviewing, and negotiating experience.
- Comfort with artificial-intelligence-assisted contract review tools and legal workflow platforms.
- Ability to distinguish standard from non-standard risk and escalate appropriately.
- Strong written communication focused on clarity, efficiency, and consistency.
- Strong organizational skills to manage multiple tasks simultaneously.
- Ability to multitask independently, be proactive, and manage varied demands.
- Ability to work in a fast-paced, business-centric environment.
- Ability and willingness to assist across the organization, including with routine tasks.
- Curiosity and desire to support colleagues across the organization.
- Ability to meet the physical demands of prolonged sitting and computer use, with visual acuity and manual dexterity to operate standard office and video-conferencing equipment; reasonable accommodations may be made.
- Serve as the primary reviewer for direct and indirect procurement contracts, including data processing agreements, using a contract lifecycle management system.
- Review contracts with artificial-intelligence-enabled tools and approved legal playbooks, identifying standard and non-standard terms and risks.
- Resolve routine contract issues independently and escalate matters to assigned attorneys when required by playbook thresholds or risk.
- Act as the primary legal negotiator through contract execution and assist with signing, following the company's Delegation of Authority policy for authorized signatories.
- Partner with direct and indirect procurement teams to support timely, business-aligned contract execution.
- Prepare risk analyses to help business stakeholders make informed negotiation decisions.
- Work with the Legal Automation team to provide feedback on contract lifecycle management system performance for reviews and negotiations.
- Monitor regulatory changes; assist with internal compliance audits; track licensing and policy renewals; and assist in updating policies.
- Support mergers, acquisitions, and financings by organizing virtual data rooms, managing closing checklists, and tracking signature packets.
- Track and coordinate completion of questionnaires and due diligence forms for prospective and existing clients.
- Assist with human-resources legal compliance, workplace policy governance, immigration tracking, and preventative risk mitigation.
- Serve as the liaison between Legal and internal stakeholders by managing legal intake, gathering information, and coordinating communications.
- Maintain minute books; manage subsidiary formations and leadership changes; and file annual reports or provide other corporate governance support.
- Support a broad and evolving range of matters and emerging needs as required.
- Corporate paralegal experience in an in-house legal department or major corporate law firm is preferred.
About the company
Covetrus is a global animal-health technology and services company that combines the distribution of veterinary products with cloud-based software and services. Its platform integrates practice management, prescription management, and client communications with an online pharmacy and home delivery to pet owners. It differentiates itself by linking physical distribution with digital infrastructure and analytics in a single ecosystem, helping practices run operations end-to-end and keep revenue within Covetrus. Its goal is to streamline veterinary workflows, improve client engagement, and support practice growth on a global scale.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Portland, Maine
Founded
2019
Get referred to Covetrus
See people who can refer or advise you
Simplify's Take
What believers are saying
- Covetrus launched free AI workflow automation at VMX 2025, improving clinic stickiness.
- The Phoenix compounding facility nearly doubled in 2025, expanding higher-margin prescription fulfillment capacity.
- Covetrus renewed its National Veterinary Associates partnership, preserving a major recurring distribution channel.
What critics are saying
- FTC demanded customer and rival information in July 2026, threatening merger delay or blockage.
- The $3.5 billion refinancing added securitization caps, signaling lender concern about balance-sheet engineering.
- The MWI integration and antitrust fight can distract management, freeze customers, and destroy the deal thesis.
What makes Covetrus unique
- Covetrus combines veterinary software, online pharmacy, and distribution in one platform.
- Its Pulse and Covetrus AI tools automate notes, summaries, and treatment workflows.
- The February 18, 2026 MWI merger would create unmatched national distribution scale.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Employee Discounts
Company Social Events
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%We are a global private equity manager that invests in and builds valuable businesses.
Direct lenders look to cap securitizations post First Brands. Private credit lenders are increasingly negotiating securitization limits into credit agreements to guard against the kind of runaway off-balance sheet financings that led to the bankruptcies of First Brands and Tricolor, according to 9fin sources. One such provision recently cleared the market in the $3.5bn refinancing that direct lenders arranged for veterinary technology platform Covetrus, sources said. When the company and its sponsor, CD&R, turned to private credit lenders led by Blue Owl to refinance its syndicated debt and upsize its facility to fund its acquisition of MWI Health, lenders took the opportunity to introduce protections that cap the amount a business can raise through accounts receivable factoring or securitization, sources said. Ultimately, such a clause would limit a borrower's ability to raise some forms off-balance-sheet financing that went largely undetected and led to the demise of companies like First Brands. Blue Owl and Covetrus declined to comment. CD&R did not respond to requests for comment. Covetrus is among a growing number of private credit-backed deals with these types of guardrails, sources told 9fin, noting that lenders in the broadly syndicated loan market are also pushing to include similar provisions in their credit documents. Read all our public content for free. You may unsubscribe from these communications at any time. Discover more insights. Use the previous and next buttons or keyboard arrows to navigate between slides.
Covetrus and MWI Animal Health plan to merge. Covetrus and MWI Animal Health plan to merge Deal would mark a significant consolidation of distributors of veterinary products Published: February 19, 2026 By Lisa Wogan Series See related stories " Covetrus_HQ VIN News Service 2023 photo Covetrus is headquartered in Portland, Maine. Covetrus has agreed to acquire MWI Animal Health in a move that will reduce to two the number of nationwide distributors of veterinary pharmaceuticals, equipment and supplies in the United States. MWI is being sold by its parent company, Cencora, for $1.25 billion in cash, plus shares that will give it a 34.3% stake in the combined company. In an announcement Wednesday, Covetrus said merging the companies will result in expanded and improved services that benefit veterinarians and their patients by making care more affordable and accessible. But some of their customers immediately raised concerns that the merger may have negative consequences because of reduced competition. Covetrus is an international company that distributes products and sells practice management software and online pharmacy services to veterinarians. The Portland, Maine-based company was created from a merger of Henry Schein Animal Health and Vets First Choice in early 2019. After a three-year stint as a public company, Covetrus was taken private by a pair of private equity firms in 2022. Based in Boise, Idaho, MWI was founded more than 50 years ago by a veterinarian to serve nearby colleagues and grew into a major veterinary distributor. It was purchased for $2.5 billion in 2015 by an international pharmaceutical company, AmerisourceBergen Corp, now named Cencora. Covetrus CEO Ben Wolin said the merger would allow the combined company to improve its logistics capabilities, "create savings" and invest in innovation. "This combination is about making animal healthcare more affordable and accessible, and we remain committed to driving innovation across the industry," he said in a press release. Cencora indicated that it would prefer to focus on other parts of its business, which include drug distribution and research in the human health care realm. "This transaction positions MWI for success with a partner strategically focused on and dedicated to animal health, while allowing Cencora to further invest in our key growth priorities," Cencora CEO Bob Mauch said. The only other major U.S. veterinary distributor is Patterson Companies. Formerly a public company, Patterson was purchased and taken private last year by Patient Square Capital, a health care investment firm. In brief * Covetrus announced plans to acquire MWI Animal Health. * The merger will reduce to two the number of nationwide distributors of veterinary pharmaceuticals, equipment and supplies. * Covetrus said the deal will make veterinary care more affordable and accessible. * The news immediately drew criticism that the merger would be unhealthy for the veterinary profession. The next largest veterinary distributor is Midwest Veterinary Supply, a family- and employee-owned company in Minnesota. There are also a handful of regional and specialized veterinary distributors. Seventeen years ago, the veterinary distribution landscape was notably different. There were six companies with national reach, according to a tally in 2009 by the executive director of the American Veterinary Distributors Association. At that time, consolidation was well underway; the association had lost 11 distributor members in seven years. To stay viable, the group later recast itself as the United Veterinary Services Association, with a membership encompassing manufacturers, suppliers and nonprofit organizations as well as distributors. Covetrus' move on MWI may draw the attention of the Federal Trade Commission, which reviews mergers and acquisitions that could substantially reduce competition. Cencora has said it expects the transaction to close after Sept. 30. The announcement does not address the future status of MWI employees. Immediate concerns voiced On the day of the announcement, James Rericha published an open letter on LinkedIn urging Cencora to spin off MWI as a standalone company rather than sell it to Covetrus. Rericha and his wife, Dr. Katie Rericha, own eight veterinary clinics in Missouri. He also urged federal regulators to listen to veterinarians' concerns when they evaluate the deal. Rericha told the VIN News Service that he is a customer of both MWI and Covetrus. He believes MWI can be a strong company on its own, to the benefit of the profession. In his letter, he describes the merger as harmful to practices like his. Merging MWI's "distribution muscle" with Covetrus' technology and services platform "creates a vertically integrated giant that controls the supply chain, the software, and the data," he writes. "For independent practices, that concentration of power raises real questions about pricing leverage, vendor lock-in, and whether the combined entity will prioritize its own platform over open interoperability." Open interoperability is the ability of systems, devices and software from different vendors to work together and easily exchange data. In contrast to a merged company, Rericha writes, "an independent MWI would have every incentive to earn customer loyalty through better service, open integrations, and competitive pricing - because it would have to." Responding to Rericha's letter, Wes Hentges, founder of Missouri-based ProPartners, a business and financial management company for veterinary clinic owners, agreed that the merger is worrisome. "On the surface, the companies say it will help vets with access and efficiency," he wrote, "but in reality, it reduces competition and puts more pricing and platform power into fewer hands. When distribution, software, and services are wrapped together, independent clinics lose leverage and choice." Hentges compared the concerns to those raised during the proposed merger of the grocery giants Kroger and Albertsons. Federal regulators blocked the merger on the basis that it would reduce competition and likely increase prices. "That same dynamic, fewer big players with more control, can hurt customers even if the companies say otherwise," Hentges wrote. A Covetrus spokesperson declined today to comment on the concerns. VIN News Service commentaries are opinion pieces presenting insights, personal experiences and/or perspectives on topical issues by members of the veterinary community. To submit a commentary for consideration, email [email protected]. Information and opinions expressed in letters to the editor are those of the author and are independent of the VIN News Service. Letters may be edited for style. We do not verify their content for accuracy.
Conduent has agreed to an all-stock merger with Covetrus, a TPG portfolio company, in a deal valuing the combined entity at approximately $3.5 billion. TPG will emerge as the controlling shareholder following the transaction's completion. The business process outsourcing company's shares surged on the announcement as investors repriced the stock around the transaction value and anticipated cost synergies. The merger combines Conduent's government, transportation and healthcare services with Covetrus's animal health technology platform. For existing Conduent shareholders, the deal offers stock in the combined company rather than cash consideration. The transaction requires shareholder and regulatory approvals before closing. Wall Street analysts view the merger as strategically positive but emphasise the need for clarity on synergy timing and leverage profile.
Covetrus, in collaboration with Zoetis Diagnostics, is creating more efficient, integrated veterinary systems, combining cutting-edge testing with practice management tools.